Compare Organon & Co. Common Stock (OGN) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Upwork Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Upwork Inc trades at $8.58 (market cap $1.05B). The key difference: Organon & Co. Common Stock is far larger — about 3.4× Upwork Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Upwork Inc for 38 Days on average.
| OGN | UPWK | |
|---|---|---|
Market Cap | $3.61B | $1.05B |
Volume | 1,808,049 | 2,045,666 |
Sector | Health | Industrials |
52-Week High | $13.81 | $22.11 |
52-Week Low | $5.70 | $7.84 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $11.03B | $815.52M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
UPWK trades at $8.64, up 0.35% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, though revenue guidance disappointed. Fundamentals show strong profitability with a 77.21% gross margin and 12.93% net margin, while valuation ratios like P/E of 11.08 and P/S of 1.49 appear reasonable. Recent news includes insider sales and a securities fraud investigation, adding uncertainty.
The outlook is mixed: analyst consensus is a Buy with a $9.64 price target, implying upside, but risks from AI disruption and legal issues persist. Earnings growth and cost management are key catalysts, though competitive pressures and volatile cash flows warrant caution for investors seeking exposure to the freelance marketplace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
